Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Aleve formulation

This article was originally published in The Tan Sheet

Executive Summary

Liquid Gels target active consumers ages 25 to 49 who suffer from back and joint pain, according to Bayer HealthCare. Available now in food, drug and mass retail outlets, Liquid Gels combine the all-day pain relieving power of Aleve (naproxen sodium) with "liquid-fast" speed and convenient dosing, according to the company. "Just two Aleve Liquid Gels can provide this all-day relief, where it would take four or even eight pills with other brands," the firm claims. The gels are sold in 20-, 40-, 80- and 160-count sizes, with suggested retail prices starting at $5.49...

You may also be interested in...

In Brief

Perrigo launches Aleve generic

California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation

CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.

CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales

Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts